Bullous Pemphigus (BP) is a common acquired immunobullous disease. PB secondary to exposure to different drugs has been described. Mesalamines, Immunomodulators (Azathioprine, cylosporine), TNF alpha antagonists (Infliximab, Adalimumab and Etanercept), IL12/23 inhibitors (Ustekinumab) have been reported to be associated with PB in the literature. We present a novel case of BP induced by Vedolizumab in a patient with UC. This is a 61 year-old male with a history of long-term pan-ulcerative colitis who was started on vedolizumab after developing lack of response or intolerance to different medications including mesalamines, Adalimumab, Golimumab and Infliximab.